Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 5 minute read Auto and Transport Industry News REV Group (REVG) stock jumps 12% on Q3 beat and higher FY2025 guidance—what’s fueling the rally? REV Group shares jump 12.6% after strong Q3 results and an upbeat FY2025 outlook. Find out what’s driving investor optimism in this stockwatch update. byPallavi MadhirajuSeptember 4, 2025